

IS REVISIONAL BARIATRIC SURGERY EFFECTIVE AND SAFE?

Dr Louise Lallemand, CHU de Nantes, FRANCE





Conflicts of interest

None


Introduction

Revision surgery after sleeve gastrectomy: a nationwide study with 10 years of follow-up

Andrea Lazzati, MD, PhD, Stéphane Bechet, MSc, Saadeddinne Journa, MD, L. Paolino, MD, Camille Jung, Md PhD



Revisional procedures by type World total of revisional procedures



- The rate of revision surgery after sleeve gastrectomy was 12.2%, at 10 years postprocedure.
- The main reason for revision surgery was: persistence of obesity (87.0%) and gastroesophageal reflux disease (5.2%).
- 15.3% patients operated for excess weight loss had a concomitant GERD.

→What about patient operated for revisional bariatric surgery without GERD?

⁽¹⁾ Senventh IFSO Global Registry Report 2022

⁽²⁾ Revision surgery after SG: a nationwide study 10 years follow-up, A Lazzati

Materiel and méthod

- Retrospective multicentric study
- 2 centers, public and private



- Patients with revisional bariatric surgery for inadequate weight loss and weight regain (%EWL<50% at 18 months)
- Patients with a RBS between 2010 and 2021.
- Exclusion criteria :
 - GERD or another complication of the first procedure (hypoglycaemia, malnutrition, anastomotic ulcer...)
 - History of adjustable gastric banding (AGB) were excluded.

Main objective


• The aim of our study was to evaluate efficacy and safety of revisional bariatric surgery on patients with failure of weight loss after bariatric surgery without GERD.



Results

- Between 2010 and 2021, 347 patients had a revisional bariatric surgery.
- We excluded 106 patients who had GERD, 76 patients with a history of AGB and 21 patients operated for another side effect of the first surgery (hypoglycaemia, malnutrition...)


→ 144 patients




First surgery - Preoperative characteristics

Gender: n (%) Female Male	116 (80.5%) 28 (19.5%)
Age: mean ± SD (years)	41.5 ± 10.9
First surgery Revisional surgery	47.2 ± 12.6
BMI: mean ± SD (kg/m2) First surgery	48.2 ± 7.6
Revisional surgery	42.4 ± 6
Smocking history: n (%)	99 (68.8%)
High Blood Pressure: n (%)	47 (32.6%)
Type 2 diabetes: n (%)	39 (27.1%)
Dyslipidemia: n (%)	27 (18.8%)
Disabling bone/joint pathology: n (%)	31 (21.5%)
OSA: n (%)	55 (38.2%)
Positive airway pressure device: n (%)	40 (72,7%)
NASH: n (%)	8 (5.5%)


First surgery



SG 74,3% N=107



RYGB 19,4% N=28



OAGB 6,9 % N=9

Post operative


• Early complications: 4.2% (n=6) patients

Late complications: 5.5% (n=8)


• The mean hospital stay was 4.9 ± 1.6 days

• The EWL% at 18 months was 43.0±50.6%






Revisional Bariatric Surgery (RBS)




RYGB 61.1% N=88



Gastric pouch resizing 13,9% N=20



OAGB 12.5% N=18



SG 9,7% N=14



SADI 2,7% N=4

Post operative

The mean hospital stay was 5.7±3.3 days.

- The EWL% at 18 months was 50.2 ± 29.4%
- 34 patients had failure in excess weight loss.
- There is no significant difference in EWL% according to the technique performed during the revisional surgery (p=0.45).
- The revisional surgery EWL% at 18 months was higher than during the first surgery significantly (p<0.01).




Post operative - complications

	First surgery, n(%)	Clavien-Dindo	Revisional surgery	Clavien-Dindo	р
Early complications	6 (4.2%)		20 (13.8%)		<0.01
Staple line hematoma	3	II	0		
Parietal bleeding	1	1	3	1	
Intra-abdominal abscess	1	IIIA	3	II	
Fever	1	1	2	1	
Anastomotic leakage	0		4	IIIB	
Anaemia	0		4	1,11	
Incisional hernia	0		1	IIIB	
Food intolerance	0		2	1	
Acute renal failure	0		2	II	
Late complications	8 (5.5%)		29 (20.1%)		<0.01
Incisional hernia	4	IIIB	5		
Adhesion intestinal obstruction	1	IIIB	1		
Internal hernia					
Anastomotic ulcer	1	II	8	IIIB	
Anastomotic stenosis	2	1	1	1	
RGO	0		5	IIIB	
Food intolerance	0		7	1	
	0		2	П	

Discussion



Revisional procedures by type World total of revisional procedures



Weight-Related Outcomes After Revisional Bariatric Surgery in Patients with Non-response After Sleeve Gastrectomy—a Systematic Review

Stephan Axer^{1,2}

○ · Hans Lederhuber³ · Franziska Stiede⁴ · Eva Szabo⁵ · Ingmar Näslund⁵

- No randomised controlled trial, studies had bias.
- Evidence-based treatment strategies cannot be deduced from the current literature
- OAGB with a 200-cm biliopancreatic limb (BPL) results in as much additional %EWL as GBP with a BPL of 100–150 cm and a common channel of 100 cm at 3 years follow-up
- Weight loss after conversion from SG to SADI is significantly higher compared to conversion from SG to GBP at the time of 4 years follow-up



Discussion - morbidity

Original article

Predictive factors of complications in revisional gastric bypass surgery: results from the Scandinavian Obesity Surgery Registry

Stephan Axer, M.D.^{a,*}, Eva Szabo, M.D., Ph.D.^b, Simon Agerskov, M.D.^c, Ingmar Näslund, M.D., Ph.D.^b

- More complications with RBS
 - Intraoperative (15.5% versus 3.0%, P < 0.001)
 - Early (24.6% versus 8.7%; P<001)
 - Late (17.7% versus 8.7%; P<001)
- Complications risk factor :
 - Laparotomy
 - intraoperative complications (OR 3.87; IC95% [2.69–5.57], P<0.001)
 - early complications (OR 2.08; IC95%, [1.53–2.83], P<0.001)
 - late complications (OR 1.91; IC95% [1.31–2.78], P<0.001)

Table 4
Univariate and multivariate analysis of variables associated with early complications in revisional gastric hypass surgery

Characteristic		Univariate analysis in	= 1680)	Multivariate analysis (n = 1656
		Odds ratio (95%CI)	P value	Odds ratio (95%CI)	P value
Age	47.4 ± 9.2	-	_	1.01 (1.00-1.03)	.08
BMI	39.6 ± 7.5		-	1.01 (1.00-1.03)	.17
Sex					
Female	343/413 (83.1%)	.0	REF		
Male	70/413 (16.9%)	1.03 (.77-1.40)	.80	S-2	-
Co-morbidities					
Sleep apnea	27/413 (6.5%)	1.90 (1.16-3.10)	.01	1.80 (1.07-3.04)	.03
Hypertension	129/413 (31.2%)	1.37 (1.08-1.75)	.01	1.08 (.82-1.42)	.49
T2D	51/413 (12.3%)	1.12 (.79-1.57)	.53	_	_
Hyperlipidemia	38/413 (9.2%)	1.18 (.80-1.75)	.40	(E)	-
Index operation					
Sleeve	10/413 (2.4%)	.0	REF	.0	REF
Adjustable bunding	129/413 (31.2%)	1.96 (.98-3.92)	.05	1.39 (.68-2.84)	.36
VBG + fixed band	274/413 (66.4%)	2,30 (1,17-4,55)	.01	1.49 (.74-3.00)	.27
Indication for revisional surgery					
Weight failure	209/413 (50.6%)	.0	REF		
Weight failure and complication	122/413 (29.5%)	.82 (.64-1.06)	.13	_	
Complication	82/413 (19.9%)	.80 (.60-1.07)	.14) <u>-</u>	- 2
Access in revisional surgery (Intenti	on-to-treat)			_	
Laparoscopy + conversion	183/413 (44.3%)	.0	REF	.0	REF
Open access	230/413 (55.7%)	2.32 (1.85-2.91)	<.001	2.08 (1.53-2.83)	<.001
Technique of the GE	STATES AND A STATE OF THE STATE				
Linear staple and handsewn	267/413 (64.6%)	.0	REF		
Completely handsewn	26/413 (6.3%)	2.15 (1.30-3.55)	.002	1.03 (.59-1.79)	.93
Circular staple	110/413 (26.6%)	1.66 (1.28-2.16)	<.001	.81 (.58-1.15)	-24
Intraoperative complication	111/413 (26.9%)	2.68 (2.03-3.53)	<.001	2.04 (1.52-2.74)	<.001

CI = confidence interval; BMI = body mass index (kg/m²); T2D = type 2 diabetes; VBG = vertical banded gastroplasty; GE = statroentero-anatomosis.

Bold font indicates variables included in the multivariate regression to identify factors independently contributing to intraoperative complications in revisional gastric bypass surgery.

Discussion – GLP-1

Use of Weight Loss Medications in Patients after Bariatric Surgery

Ilana P. Redmond 100 - Alpana P. Shukla 1 - Louis J. Aronne 1

Accepted: 11 January 2021

The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021

Table 1 Summary of prospective studies of pharmacotherapy for postoperative weight management

Source	Intervention	Number of patients	Patient characteristics	Time clapsed since surgery	Duntion of follow-up	Outcomes
Zoss et al. (2002)	AGB with orients 120 mg TID + dictary counseling (O) vs dictary counseling (DC)	O=19 DC=19	Post-surgical patients who had stopped losing weight for 3 months	18±6 months	8 months, with partial 9 month extension	% total weight loss O=8.25 DC=3.19 (p<.03)
Zilberstein et al. (2004)	AGH with topiramate 12.5-50 mg/day (T)	T=16	Post-surgical putients with insdequate weight loss	Range 5-13 months	3 months	% excess weight loss (mean) T=13.2
And et al. (2019)	LSG with phestermine/ topirumate 7.5/46-15/92 mg/day (PT) vs hinterical controls (BC)	PT=15 HC=40	Super obese patients started on PT 3 months preoperatively and continued postoperatively	Not applicable	24 months	% total weight loss PT=38.16 (30.94-45.39) HC=27 (22.99-31.02) (p=.007)
Sulman et al. (2019)	Linghitide 3 mg/day in nonsorgical (NS) and surgical (S)	NS=711 S=76	Patients with a BMI ≥ 30 kg/m ² or ≥27 kg/m ² with comorbidities	Median 4 years	4 months	% total weight loss (modian) NS=6.4 (2.5-9.8) S=6.1 (3.1-8.7)

-3,8kg after 2 years



THE LANCET Diabetes & Endocrinology



Volume 7, Issue 7, July 2019, Pages 549-559

Articles

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial

Table 2. Results of multivariable linear regression analyses of the change from baseline to 26 weeks in clinical outcome variables in complete-cases population.

Covariates were baseline values of the outcome variable, treatment assignment (Liragilutide vs Placebo) and type of surgery (VSO vs RYOB). Coefficients for each covariate listed. Significant p-values <0.05 highlighted in bold. LDL, low-density lipoprotein; HDL, high-density lipoprotein; TO, traglycerides.

Primary endpoint		Baseline value		Treatme	Treatment (Liraghetide vs Placebo)		Type of Surgery (VSG 11 RYGB)		RYGB)
	Coefficient	95% CS	p-value:	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value
HhA1c (mmol/mol)	0.70	0-48 to 0-91	<0.001	-13:3	-19-7 to -7-0	<0.001	4-67	-11-4 to 2.0	0-169
HhAle (% umis)	0.06	0-04 to 0-08		-1:22	-1:22 -1:50 to -0:54	-0-43	0-45 -1-04 to 0-18		
ferrom, respective									
Weight (kg)	0.95	0 89 to 1 00	<0-001	-4-23	-6:51 to -1:64	9-002	-2-04	-5-00 to 0-93	0-175
near (menerg)	0.03	0.47.50.0.94	<6-861	2.14	-9:32 to 8:80	0.323	12.99	10.80 (0.7.81	0.246
DBP (mmHg)	0.51	0:33 to 0:70	<0.001	2.68	-1-67 to 7-44	0.211	-1-41	-6-36 to 3-55	0-573
Total Cholesterol (mmol/L)	0.58	0-42 to 0-75	<0.001	-0-03	-0-41 to 0-35	0.879	-0:36	-0-77 to 0-05	0.087
LDL cholesterol (mmol L)	0.73	0-55 to 0-92	<0.001	0.04	-0 29 to 0:37	0.815	-0:23	-0:58 to 0:13	0.213
HDL cholesterol (mmoEL)	0.89	0-74 to 1-01	<9-001	0-03	-0:08 to 0:11	0.545	-0-01	-0-15 to 0-09	0.622
Triglycerides (mmol L)	0.18	0 10 to 0-25	< 0.001	-0-26	-0:56 to 0:04	0.089	-0-29	-0-61 to 0-04	0.061
King's Obesity Staging Criteria	0.64	0.70 to 0.98	<0.001	0-23	-0 87 to 1:32	0.682	-0-66	-1 file to 0:53	0-273

Conclusion


• RBS is efficient to treat failure in EWL and weight regain

RBS is associated with higher morbidity

An association of surgery with GLP1 treatment is maybe a good option



Thank you for your attention



No significant difference P = 0,45

Revisional Bariatric Surgery for Unsuccessful Weight Loss and Complications

Hideharu Shimizu • Shohrat Annaberdyev • Isaac Motamarry • Matthew Kroh • Philip R. Schauer • Stacy A. Brethauer

Table 4 Weight loss results according to the type of primary bariatric procedures in the unsatisfactory weight loss group. A total of 97 (92.4 %) of 105 patients were included in the analysis for weight loss outcomes with >1 year follow-up

BMI body mass index, *BW* body weight, *EWL* excess weight loss ^a Defined as BMI at primary bariatric surgery

^b Defined as the period from primary bariatric surgery to revisional surgery

Variable	Primary restrictive (n=66)	Primary bypass (<i>n</i> =31)	P
Initial BMI ^a	57.2±15.4	56.6±12.4	0.8
Initial BW	159.2±52.1	157.5±42.8	0.9
Interval ^b	9.2 ± 10.8	8.6±7.9	0.8
BMI at revision	51.6±12.2	47.0±8.5	0.04
BW at revision	143.9 ± 42.5	131.7±31.6	0.1
Follow-up period	2.5±1.4	1.9±0.9	0.02
BMI at follow-up	37.5±11.8	38.9 ± 9.2	0.9
BW at follow-up	106.7±41.2	110.8±31.9	0.7
EWL from revision	53.7±29.3	37.6±35.1	0.03
≥50 % EWL from revision	38 (57.6 %)	11 (35.5 %)	0.04
EWL from primary surgery	62.4±24.1	55.4±24.8	0.2
≥50 % EWL from primary surgery	42 (63.6 %)	16 (51.6 %)	0.2

Revisional Bariatric Surgery for Unsuccessful Weight Loss and Complications

Hideharu Shimizu · Shohrat Annaberdyev · Isaac Motamarry · Matthew Kroh · Philip R. Schauer · Stacy A. Brethauer

Table 4 Weight loss results according to the type of primary bariatric procedures in the unsatisfactory weight loss group. A total of 97 (92.4 %) of 105 patients were included in the analysis for weight loss outcomes with >1 year follow-up

BMI body mass index, *BW* body weight, *EWL* excess weight loss ^a Defined as BMI at primary bariatric surgery

^b Defined as the period from primary bariatric surgery to revisional surgery

Variable	Primary restrictive (n=66)	Primary bypass (<i>n</i> =31)	P
Initial BMI ^a	57.2±15.4	56.6±12.4	0.8
Initial BW	159.2±52.1	157.5±42.8	0.9
Interval ^b	9.2 ± 10.8	8.6±7.9	0.8
BMI at revision	51.6±12.2	47.0±8.5	0.04
BW at revision	143.9 ± 42.5	131.7±31.6	0.1
Follow-up period	2.5±1.4	1.9 ± 0.9	0.02
BMI at follow-up	37.5±11.8	38.9 ± 9.2	0.9
BW at follow-up	106.7±41.2	110.8±31.9	0.7
EWL from revision	53.7±29.3	37.6±35.1	0.03
≥50 % EWL from revision	38 (57.6 %)	11 (35.5 %)	0.04
EWL from primary surgery	62.4±24.1	55.4±24.8	0.2
≥50 % EWL from primary surgery	42 (63.6 %)	16 (51.6 %)	0.2

Predictive factors for failure in EWL

	EWL%<50%	EWL%>50%	OR (IC95%)	р
Age (years): mean ± SD	57.8±9.6	51.3±11.9	1,06(1.01-1.11)	0.03
Gender Male Female	6 28	4 24	0.12(0.32-5.10)	0.7
Smocking history No n Yes n	23 10	17 11	0.32(0.26-2.1)	0.7
First surgery BMI : mean± SD	53.5±7.8	47.2±6.6	1,14(1.04-1.24)	<0.01
Revisional surgery BMI : mean ±SD	46.5±6.1	44.1±15.3	0.83(0.97-1.10)	0.36
First surgery EWL% at 18 months : mean ± SD	8.5±43.7	48.2±32.4	0,97(0.95-0.99)	<0.01
Time between the two surgery	42.2±31.7	49.9±28.0	0.96(0.97-1.01)	0.32

Discussion – predictive factors

Post operative follow up+++

- High preoperative weight
- young age
- Male gender
- Correlations between predicted weight and real weight

Older age

- Unemployment
- Hypertension
- Number of comorbidities

Postoperative Follow-up After Bariatric Surgery: Effect on Weight Loss

Konstantinos Spaniolas¹ · Kevin R. Kasten¹ · Adam Celio¹ · Matthew B. Burruss¹ · Walter J. Pories¹

Does Patient Compliance with Follow-up Influence Weight Loss After Gastric Bypass Surgery? A Systematic Review and Meta-Analysis

Hyun Joon Kim · Aman Madan · Douglas Fenton-Lee

A Predictive Model of Weight Loss After Roux-en-Y Gastric Bypass up to 5 Years After Surgery: a Useful Tool to Select and Manage Candidates to Bariatric Surgery

Kevin Seyssel 10 · Michel Suter 23 · François Pattou 4 · Robert Caiazzo 4 · Helene Verkindt 4 · Violeta Raverdy 4 · Mathieu Jolivet 5.6 · Emmanuel Disse 6.7 · Maud Robert 5.6 · Vittorio Giusti 8

Are there really any predictive factors for a successful weight loss after bariatric surgery?



Diego Cadena-Obando¹, Claudia Ramírez-Rentería², Aldo Ferreira-Hermosillo³, Alejandra Albartán-Sanchez⁴, Ernesto Sosa-Eroza¹, Mario Molina-Ayala¹ and Etual Espinosa-Cárdenas^{1*}

Conclusion

RBS is efficient to treat failure in EWL and weight regain

RBS is associated with higher morbidity

• High age, high first surgery BMI and low first surgery EWL% at 18 months seem to be predictive of failure in weight loss.